Allegiance Completes Private Placement of 350,000 Common at $0.27 Per Share
20 Février 2012 - 2:33PM
PR Newswire (Canada)
TORONTO, Feb. 21, 2012 /CNW/ - Allegiance Equity Corporation The
TSX has given final approval to the purchase by Palm American
Investment Inc. of 350,000 common shares of Allegiance Equity
Corporation at $0.27 per share. The private placement shares are
restricted and cannot be sold or transferred until June 30th 2012.
Purpose of Financing The funds will be used for general corporate
purposes and the maintenance of its patents. Allegiance is very
fortunate that its partners absorb thew majority of the expenses
for research product development regulatory filings and ongoing
trials. Company Profile Allegiance develops products for mass
market opportunities having clearly identified product deficiencies
and dissatisfied patients and consumers who suffer widespread
diseases and conditions including diabetes, Alzheimer's and
Dementia and inflammatory skin conditions. Allegiance then obtains
patents, regulatory approvals and licenses these technologies for
royalty's upfront fees and royalties. Allegiance's strategy
utilizes leading-edge scientific technology to create valuable,
proprietary and effective natural treatments, recognized as safe
and effective by North American regulatory authorities, at a
fraction of the cost and time it takes to develop a prescription
drug. Allegiance then obtains patents and regulatory approvals.
Proprietary Technologies and Recent Developments Allegiance and its
partners developed and patented CinGx™ and Relieva™ providing
millions of dollars in licensing opportunities. Both products are
ready for market and the company is in engaged in negotiations with
major potential licensees world-wide. Allegiance has partnered with
DSE Health Solutions Inc. for the marketing of Relieva™ and
Nealanders International Inc. for the marketing CinGx™, both world
class companies and leaders in their respective industries ABOUT
CING-X™ Allegiance Equity Corporation recently developed CinGx™, a
unique product to treat and prevent Type 3 Diabetes resulting from
the impact of Diabetes on brain function. CinGx™ is a formula
combining two extracts which act synergistically to control glucose
metabolism, improve cognitive function and simultaneously minimize
the risk of developing and treating CVD, diabetes, dementia and
Alzheimer's. CinGx™ is a proprietary additive that enhances the
value of any food, beverage or nutritional supplement and can be
combined with most other ingredients Only CinGx™ improves blood
glucose metabolism while increasing mental and physical capacity.
Interest of Management Palm American Investment Inc. will continue
to be the controlling shareholder of Allegiance holding 2,060,997
common shares. Palm American Investment Inc. is controlled by David
Solomon, Marilyn Bloovol and members of their family There will be
7,641,087 common shares of Allegiance issued and outstanding.
Additional information relevant to the Company's activities,
including the Company's press releases can found on SEDAR at
www.sedar.com The TSX Venture Exchange has not reviewed and does
not accept responsibility FOR THE ADEQUACY OR ACCURACY FOR THIS
PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT. Contacts:
Allegiance Equity Corporation David Solomon President (416) 630
1221 Email dsolomon79@gmail.com SOURCE Allegiance Equity
Corporation Allegiance Equity Corporation
Copyright
(TSXV:ANQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(TSXV:ANQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (TSX Venture Exchange): 0 recent articles
Plus d'articles sur Allegiance Equity Corp